ArticlePloS one2016
Chlamydia trachomatis Pgp3 Antibody Persists and Correlates with Self-Reported Infection and Behavioural Risks in a Blinded Cohort Study.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 60 citations in OpenAlex.
- Double-antigen sandwich ELISA based on chimeric antigens for detection of antibodies to Trypanosoma cruzi in human sera - A phase II study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Review
- Serum IgG1 and IgG3 Antibodies to Chlamydia trachomatis Pgp3 and Hsp60 in Men of Subfertile Couples.The Journal of infectious diseases · 2026Article
- Circulating biomarkers of infection and endometrial cancer risk.Cancer causes & control : CCC · 2025Article
- UnveilingiScience · 2025Article
- Serum IgG1 and IgG3 Antibody Responses to Chlamydia trachomatis Pgp3 and Hsp60 in Tubal Factor Infertility.The Journal of infectious diseases · 2025Article
- Maternal-fetal transfer and longitudinal trends of antibodies to Chlamydia trachomatis and Mycoplasma genitalium in early childhood.Acta obstetricia et gynecologica Scandinavica · 2025Article
- Risk factors associated with IgG seropersistence toEpidemiology and infection · 2025Article
- Prevalence and risk factors for Chlamydia trachomatis seropositivity and seropersistence among women: A prospective cohort study.PloS one · 2025Article
- Seroprevalence of sexually transmitted infections over 44 years - A cross-sectional study in Sweden.International journal of STD & AIDS · 2024Article
- Chlamydia trachomatis Seroassays Used in Epidemiologic Research: A Narrative Review and Practical Considerations.The Journal of infectious diseases · 2024Review
- Characterization of genital chlamydia trachomatis infection among women attending infertility and gynecology clinics in Hunan, China.BMC infectious diseases · 2024Article
- The serodiagnositic value ofFrontiers in public health · 2024Article
- Antibody responses toFrontiers in cellular and infection microbiology · 2024Article
- Using infection prevalence, seroprevalence and case report data to estimate chlamydial infection incidence.Sexually transmitted infections · 2023Article
- Sexually Transmitted Infections and Risk of Epithelial Ovarian Cancer: Results From the Finnish Maternity Cohort.The Journal of infectious diseases · 2023Article
- Association between serumFrontiers in public health · 2023Article
- Plasmid-mediated virulence inFrontiers in cellular and infection microbiology · 2023Review
- Investigating the effect of sexual behaviour on oropharyngeal cancer risk: a methodological assessment of Mendelian randomization.BMC medicine · 2022Article
- High Plasmid Gene Protein 3 (Pgp3) Chlamydia trachomatis Seropositivity, Pelvic Inflammatory Disease, and Infertility Among Women, National Health and Nutrition Examination Survey, United States, 2013-2016.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chlamydia trachomatis (Ct) serological studies in populations could help monitor changes in lifetime cumulative risk of infection. We developed a double-antigen sandwich ELISA based on the Ct-specific Pgp3 antigen, then tested blind stored sera from over 800 participants in a New Zealand birth cohort from Dunedin at ages 26, 32 and 38. The double-antigen sandwich ELISA was more sensitive than our previously characterised indirect Pgp3 ELISA. Pgp3 antibody was detected more often in women compared to men and correlated with increasing numbers of sexual partners, self-reported Ct, and younger age at sexual debut in both women and men. At age 26, 24.1% (99/411) of women were Pgp3 seropositive, as were 79.5% (35/44) of those reporting Ct infection; Pgp3 antibody persisted to age 38 in 96.5% (83/86). In men at age 26, the figures were 10.7% (47/442) and 25.0% (6/24), respectively, with high (83.9%) antibody persistence to age 38. At age 38, among those Pgp3 seropositive, 63.3% of women and 83.1% of men had not reported Ct infection. Thus, Ct-specific Pgp3 antibody was detected in most women reporting Ct infection and correlated with risk of infection in those who did not, with most infections remaining undetected. As this antibody persisted for at least twelve years in 96% of these women, serology could be used to evaluate Ct prevention programmes among women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.